ELAN 351 Extension - A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with AD who Participated in Study ELN115727-301 or ELN115727-302

Grants and Contracts Details

StatusFinished
Effective start/end date5/13/10 → 4/30/14

Funding

  • Janssen Alzheimer Immunotherapy Research and Development LLC: $206,766.00